- Home
- BCAL vs DBVT Comparison
BCAL vs DBVT Comparison
Compare BCAL & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAL
- DBVT
- Stock Information
- Founded
- BCAL 2001
- DBVT 2002
- Country
- BCAL United States
- DBVT France
- Employees
- BCAL N/A
- DBVT N/A
- Industry
- BCAL Major Banks
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAL Finance
- DBVT Health Care
- Exchange
- BCAL Nasdaq
- DBVT Nasdaq
- Market Cap
- BCAL 528.7M
- DBVT 464.0M
- IPO Year
- BCAL N/A
- DBVT N/A
- Fundamental
- Price
- BCAL $17.29
- DBVT $15.49
- Analyst Decision
- BCAL Buy
- DBVT Buy
- Analyst Count
- BCAL 2
- DBVT 4
- Target Price
- BCAL $19.50
- DBVT $14.81
- AVG Volume (30 Days)
- BCAL 110.4K
- DBVT 191.0K
- Earning Date
- BCAL 10-24-2025
- DBVT 10-30-2025
- Dividend Yield
- BCAL N/A
- DBVT N/A
- EPS Growth
- BCAL 15.70
- DBVT N/A
- EPS
- BCAL 0.99
- DBVT N/A
- Revenue
- BCAL $157,669,000.00
- DBVT $3,800,000.00
- Revenue This Year
- BCAL $71.01
- DBVT $1,743.46
- Revenue Next Year
- BCAL $2.69
- DBVT $1,044.34
- P/E Ratio
- BCAL $17.44
- DBVT N/A
- Revenue Growth
- BCAL 80.55
- DBVT N/A
- 52 Week Low
- BCAL $11.87
- DBVT $2.21
- 52 Week High
- BCAL $18.49
- DBVT $18.00
- Technical
- Relative Strength Index (RSI)
- BCAL 57.13
- DBVT 61.67
- Support Level
- BCAL $16.61
- DBVT $14.85
- Resistance Level
- BCAL $17.55
- DBVT $17.90
- Average True Range (ATR)
- BCAL 0.54
- DBVT 1.15
- MACD
- BCAL 0.01
- DBVT -0.13
- Stochastic Oscillator
- BCAL 77.98
- DBVT 41.89
About BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.